Indonesia’s biggest pharmaceutical company plans to close five factories within the next two or three years in a measure that its director of production and supply chain attributed to the need to ensure sustainability.
ndonesia’s biggest pharmaceutical company, PT Kimia Farma, has announced plans to close five factories within the next two or three years. The company’s director of production and supply chain, Hadi Kardoko, said on Tuesday the measure was needed to ensure sustainability.
“Of course, in rationalizing, we need to carefully consider business continuity and take into account the prevailing regulations,” Hadi said on Tuesday during the company’s annual general meeting of shareholders, as quoted by Detik.
He added that the closing of pharmaceutical factories would take time and that the company would take into account the market impacts of such a move.
"We must not cut off the availability of medicines, otherwise there will be none. This is why we need two to three years, besides [the need to comply with] regulations," Hadi said.
The director said the plan to close five factories of the state-owned enterprise was aimed at optimizing the operations across the firm’s production facilities, and he expressed confidence that the measure would reduce high operational costs.
Read also: Analysis: Post-pandemic, pharma SOEs beset with financial problems
"In doing so, we hope that, if yesterday showed our three-shift utilization amounted to less than 40 percent [capacity utilization], carrying out this plan will increase our utilization rate to above 40 percent and lead to greater efficiency,” he said.
Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.
Thank you for sharing your thoughts. We appreciate your feedback.
Quickly share this news with your network—keep everyone informed with just a single click!
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
Get the best experience—faster access, exclusive features, and a seamless way to stay updated.